Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1660908 | 0.87 | MTNR1A (0.33) | ALDH1A1 | |
| SCHEMBL16099547 | 0.85 | ALDH1A1 (0.31) | ALDH1A1CYP3A4GRIN2BMAOB | |
| SCHEMBL16099270 | 0.83 | CYP3A4 (0.30) | CYP3A4 | |
| SCHEMBL16100069 | 0.81 | CYP3A4 (0.30) | CYP3A4 | |
| SCHEMBL3164039 | 0.77 | GRIN2B (0.37) | GRIN2B | |
| SCHEMBL9222201 | 0.76 | ALDH1A1 (0.30) | ALDH1A1CYP3A4 | |
| SCHEMBL630041 | 0.73 | CYP3A4 (0.33) | ALDH1A1CYP3A4GRIN2B | |
| SCHEMBL629913 | 0.73 | CYP3A4 (0.33) | ALDH1A1CYP3A4GRIN2B | |
| SCHEMBL16098780 | 0.73 | ALDH1A1 (0.31) | ALDH1A1CYP3A4GRIN2B | |
| SCHEMBL16094286 | 0.72 | CYP3A4 (0.30) | CYP3A4GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7648966-B2 | Mannose-6-phosphonate compounds for the treatment of inflammatory diseases | Pharmaxis Pty Limited (AU) | 2010-01-19 | — | — | US | disclosed |
| EP-1628987-B1 | MANNOSE-6-PHOSPHONATE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | PHARMAXIS PTY LTD (AU) | 2009-08-19 | — | — | EP | disclosed |
| US-20070082850-A1 | Mannose-6-phosphonate compounds for the treatment of inflammatory diseases | PHARMAXIX PTY LTD (AU) | 2007-04-12 | — | — | US | disclosed |
| EP-1628987-A2 | MANNOSE-6-PHOSPHONATE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Pharmaxis Pty Ltd. (AU) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004104015-A2 | MANNOSE-6-PHOSPHONATE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | PHARMAXIS PTY LTD. (AU) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082850-A1 | Mannose-6-phosphonate compounds for the treatment of inflammatory diseases | PMM2, CD4, MPI | ALDH1A1 2152/4885CYP3A4 4047/4885GRIN2B 4119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.